Bamco Inc. NY Decreases Position in DexCom, Inc. (NASDAQ:DXCM)

Bamco Inc. NY trimmed its position in DexCom, Inc. (NASDAQ:DXCM - Free Report) by 23.4% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 432,500 shares of the medical device company's stock after selling 132,354 shares during the quarter. Bamco Inc. NY owned approximately 0.11% of DexCom worth $33,636,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in the business. Forvis Mazars Wealth Advisors LLC increased its stake in shares of DexCom by 0.7% during the fourth quarter. Forvis Mazars Wealth Advisors LLC now owns 17,481 shares of the medical device company's stock worth $1,359,000 after acquiring an additional 118 shares during the period. Principal Securities Inc. boosted its position in shares of DexCom by 3.4% in the fourth quarter. Principal Securities Inc. now owns 4,069 shares of the medical device company's stock worth $316,000 after buying an additional 135 shares during the period. Larson Financial Group LLC boosted its stake in shares of DexCom by 40.5% in the fourth quarter. Larson Financial Group LLC now owns 475 shares of the medical device company's stock valued at $37,000 after purchasing an additional 137 shares during the period. Level Four Advisory Services LLC grew its stake in shares of DexCom by 1.1% during the fourth quarter. Level Four Advisory Services LLC now owns 13,196 shares of the medical device company's stock valued at $1,026,000 after acquiring an additional 150 shares in the last quarter. Finally, Covestor Ltd grew its stake in DexCom by 15.6% during the 4th quarter. Covestor Ltd now owns 1,109 shares of the medical device company's stock valued at $86,000 after purchasing an additional 150 shares in the last quarter. 97.75% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of brokerages recently weighed in on DXCM. Morgan Stanley boosted their price objective on shares of DexCom from $75.00 to $82.00 and gave the company an "equal weight" rating in a research report on Friday, February 14th. Wells Fargo & Company reissued an "overweight" rating on shares of DexCom in a research note on Saturday, March 8th. Piper Sandler decreased their target price on DexCom from $100.00 to $90.00 and set an "overweight" rating for the company in a research note on Friday, May 2nd. Mizuho assumed coverage on DexCom in a report on Thursday, April 10th. They issued an "outperform" rating and a $85.00 price target on the stock. Finally, Redburn Atlantic raised shares of DexCom from a "neutral" rating to a "buy" rating and lifted their target price for the stock from $85.00 to $115.00 in a research report on Monday, February 3rd. Five research analysts have rated the stock with a hold rating, thirteen have issued a buy rating and three have assigned a strong buy rating to the company. According to MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and an average target price of $98.11.

Insiders Place Their Bets

In other news, COO Jacob Steven Leach sold 14,076 shares of DexCom stock in a transaction that occurred on Wednesday, March 12th. The shares were sold at an average price of $70.38, for a total transaction of $990,668.88. Following the completion of the sale, the chief operating officer now owns 313,497 shares of the company's stock, valued at approximately $22,063,918.86. The trade was a 4.30 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, EVP Michael Jon Brown sold 13,000 shares of the business's stock in a transaction dated Wednesday, March 12th. The shares were sold at an average price of $70.38, for a total transaction of $914,940.00. Following the completion of the sale, the executive vice president now owns 105,602 shares of the company's stock, valued at approximately $7,432,268.76. This represents a 10.96 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 66,926 shares of company stock worth $4,734,384 in the last 90 days. 0.32% of the stock is currently owned by corporate insiders.

DexCom Trading Up 2.2 %

Shares of DexCom stock traded up $1.82 on Wednesday, hitting $83.35. The stock had a trading volume of 3,944,543 shares, compared to its average volume of 4,294,290. The stock's 50-day simple moving average is $71.05 and its two-hundred day simple moving average is $77.00. DexCom, Inc. has a one year low of $57.52 and a one year high of $132.26. The stock has a market cap of $32.68 billion, a price-to-earnings ratio of 58.29, a PEG ratio of 2.30 and a beta of 1.43. The company has a quick ratio of 1.28, a current ratio of 1.47 and a debt-to-equity ratio of 0.59.

DexCom (NASDAQ:DXCM - Get Free Report) last released its quarterly earnings results on Thursday, May 1st. The medical device company reported $0.32 earnings per share for the quarter, missing the consensus estimate of $0.33 by ($0.01). The firm had revenue of $1.04 billion for the quarter, compared to the consensus estimate of $1.02 billion. DexCom had a net margin of 14.29% and a return on equity of 30.14%. The company's revenue for the quarter was up 12.5% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $0.32 earnings per share. As a group, sell-side analysts predict that DexCom, Inc. will post 2.03 EPS for the current year.

About DexCom

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.